Qure ai Technologies Pvt Ltd

Qure.ai Technologies Pvt Ltd, founded in 2016, builds deep learning software that reads medical images. Its AI-powered radiology interpretation solutions analyze X-rays and CT scans to identify and manage lung cancer, tuberculosis, pediatric TB, and stroke across lung, brain, and other diagnostic areas. The work sits at the intersection of computer vision and clinical practice: models trained to surface findings that radiologists and clinicians act on, in settings where a misread has real consequences.

For anyone thinking about the security and integrity of clinical systems, the deployment surface is the story. Qure.ai's software runs at more than 5,500 sites across over 105 countries, and has received multiple FDA clearances - meaning it operates inside regulated medical device pipelines, alongside patient imaging data, diagnostic workflows, and hospital IT environments that were not designed with a modern threat model in mind. Distribution at that scale implies a wide perimeter: on-prem imaging stacks, regional data residency requirements, and integration points with PACS and clinical infrastructure that vary site to site.

The technical domains are deep learning, artificial intelligence, computer vision, medical imaging analysis, and radiology interpretation. The company reports 45 million+ lives impacted and $130M in capital raised, and was named to TIME's 100 Most Influential Companies of 2025. Its stated mission is to make healthcare more equitable, accessible, and affordable - a framing that, in practice, means shipping diagnostic AI into public health and low-resource settings where uptime, data handling, and model reliability are not abstract concerns.